The potential of proteasome inhibitors in cancer therapy

Authors:
  • IMIvana von Metzler
    Ivana von Metzler
  • JHJens-Claus Hahne
    Jens-Claus Hahne
  • BLBritta Lamottke
    Britta Lamottke
  • JRJessica Rademacher
    Jessica Rademacher
  • UHUlrike Heider
    Ulrike Heider
  • ETEvangelos Terpos
    Evangelos Terpos
  • OSOrhan Sezer
    Orhan Sezer

Abstract
Background: The ubiquitin-proteasome system has become a promising novel molecular target in cancer due to its critical role in cellular protein degradation, its interaction with cell cycle and apoptosis regulation and its unique mechanism of action. Objective: This review focuses both on preclinical results and on data from clinical trials with proteasome inhibitors in cancer. Methods: Results in hematological malignancies and solid tumors were included, and important data presented in abstract form were considered in this review. Results/conclusion: Bortezomib as first-in-class proteasome inhibitor has proven to be highly effective in some hematological malignancies, overcomes conventional chemoresistance, directly induces cell cycle arrest and apoptosis, and also targets the tumor microenvironment. It has been granted approval by the FDA for relapsed multiple myeloma, and recently for relapsed mantle cell lymphoma. Combination chemotherapy regimens have been developed providing high remission rates and...

This publication has 107 references indexed in Scilit: